HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 12, December 2018 – The story of WeDoctor - The medical service system for tomorrow       » World's first unmanned clinic in China       » International outcry over world's first gene-edited babies born in China       » More HIV-positive foreigners enter China       » Pain-free childbirth to be promoted in China       » The past, present and future of life science      
EYE ON CHINA
First China-developed drug for colorectal cancer approved in China
Chi-Med announces approval of fruquintinib capsules for previously treated colorectal cancer in China

Hutchison China MediTech Limited (Chi-Med) announced that fruquintinib capsules have been granted approval for drug registration by the National Medical Products Administration of China (NMPA, formerly the China Food and Drug Administration) for the treatment of metastatic colorectal cancer (CRC) patients, who have failed at least two prior systemic antineoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) therapies.

Fruquintinib is a highly selective and potent small molecule oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 designed to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Fruquintinib capsules are to be marketed in China under the brand name Elunate. The approval is based on results from the Phase III FRESCO trial, which were presented at the American Society of Clinical Oncology 2017 Meeting and published in the Journal of the American Medical Association in 2018.

Simon To, chairman of Chi-Med said, “Elunate is the first home-grown, China-discovered and developed drug we are aware of in an oncology indication to be unconditionally approved through a randomized clinical trial in China,” he added,

CRC is the second most common cancer type in China, with about 380,000 new cases per year. There were approximately 1.5 million new CRC cases globally in 2015 which are expected to increase to approximately 1.7 million new cases per year by 2020, according to Frost & Sullivan.

The market launch of Elunate in China will be through collaborating with Eli Lilly & Company (Lilly), which involves an approximately US$13.6 million milestone payment to Chi-Med from Lilly.

Source: Chi-Med

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy